Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare Biotechnology
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

GlobeNewswire February 8, 2024

Collegium Provides 2024 Financial Guidance

GlobeNewswire January 3, 2024

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

GlobeNewswire November 27, 2023

Collegium Announces $25 Million Accelerated Share Repurchase Program

GlobeNewswire November 9, 2023

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire November 8, 2023

Collegium Reports Third Quarter 2023 Financial Results

GlobeNewswire November 7, 2023

Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023

GlobeNewswire October 24, 2023

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

GlobeNewswire August 28, 2023

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

GlobeNewswire August 24, 2023

Collegium Announces $50 Million Accelerated Share Repurchase Program

GlobeNewswire August 7, 2023

Collegium Reports Record 1H'23 Net Revenue of $280.3 Million, Up 35% Year-over-Year

GlobeNewswire August 3, 2023

Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023

GlobeNewswire July 20, 2023

Collegium to Participate in Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Collegium Reports First Quarter 2023 Financial Results

GlobeNewswire May 4, 2023

Collegium to Report First Quarter 2023 Financial Results on May 4, 2023

GlobeNewswire April 20, 2023

Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 11, 2023

Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

GlobeNewswire February 23, 2023

Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report

GlobeNewswire February 22, 2023

Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering

GlobeNewswire February 7, 2023

Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering

GlobeNewswire February 6, 2023